FDA Approvals, Scheduled Presentations, and Stock Price Movements - Research Report on Amgen, St. Jude Medical, Life

 FDA Approvals, Scheduled Presentations, and Stock Price Movements - Research
  Report on Amgen, St. Jude Medical, Life Technologies, Ligand, and Infinity
                               Pharmaceuticals

PR Newswire

NEW YORK, November 29, 2013

NEW YORK, November 29, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Amgen,
Inc. (NASDAQ: AMGN), St. Jude Medical, Inc. (NYSE: STJ), Life Technologies
Corp. (NASDAQ: LIFE), Ligand Pharmaceuticals Inc. (NASDAQ: LGND), and Infinity
Pharmaceuticals Inc. (NASDAQ:INFI). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Amgen, Inc. Research Report

On November 22, 2013, Onyx Pharmaceuticals, a subsidiary of Amgen, Inc.
(Amgen), and Bayer Healthcare Pharmaceuticals Inc. together announced that the
US Food and Drug Administration (FDA) approved a supplemental New Drug
Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets
for the treatment of patients with locally recurrent or metastatic,
progressive, differentiated thyroid carcinoma (DTC) refractor to radioactive
iodine treatment. Amgen stated that the FDA approval is based on the results
of the DECISION (stuDy of sorafEnib in loCally advanced or metastatIc patientS
with radioactive Iodine refractory thyrOid caNcer) trial, an international,
multicenter, placebo-controlled study. Commenting on the news, Pamela A.
Cyrus, M.D., Vice President and Head of U.S. Medical Affairs, Bayer Healthcare
Pharmaceuticals, stated, "Locally recurrent or metastatic, progressive,
differentiated thyroid carcinoma that is refractory to radioactive iodine
treatment is difficult to treat. NEXAVAR is the first and only FDA-approved
therapy for this type of thyroid cancer and is a positive development for
patients who previously had limited treatment options." The Company informed
that NEXAVAR was approved following a priority review by the FDA, a
designation reserved for drugs that may offer a significant improvement in
treatment over existing options.The Full Research Report on Amgen, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/e96b_AMGN

St. Jude Medical, Inc. Research Report

On November 21, 2013, St. Jude Medical, Inc. (St. Jude Medical) announced that
the Company will present at the Piper Jaffray 25^th Annual Healthcare
Conference on December 3, 2013, in New York City. The Company informed that
Don Zurbay, Vice President, Finance and CFO will address the conference at
9:30 a.m. ET. St. Jude Medical stated that the live webcast of the
presentation will be available at the Company website. The Full Research
Report on St. Jude Medical, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/b338_STJ

Life Technologies Corp. Research Report

On November 26, 2013, Life Technologies Corp.'s (Life Technologies) stock rose
0.08%, ending the day at $75.75. Over the previous three trading sessions,
shares of Life Technologies gained 0.16% compared to the Nasdaq Composite
which gained 1.22% during the same period. The Full Research Report on Life
Technologies Corp. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/d5de_LIFE

Ligand Pharmaceuticals Inc. Research Report

On November 26, 2013, Ligand Pharmaceuticals Inc.'s (Ligand) stock rose 5.48%,
ending the day at $57.75. Over the previous three trading sessions, shares of
Ligand gained 11.08% compared to the Nasdaq Composite which gained 1.22%
during the same period. The Full Research Report on Ligand Pharmaceuticals
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/3b8d_LGND

Infinity Pharmaceuticals Inc. Research Report

Infinity Pharmaceuticals Inc. (Infinity Pharmaceuticals) posted the schedule
of its upcoming conferences and events on the events section of its Company
website. The Company stated that it will present at the Deutsche Bank BioFEST
Conference in Boston, Massachusetts on December 2, 2013 at 10:10 a.m. ET, and
will host ASH Investor Reception and Webcast, on December 8, 2013 at 12:00
p.m. ET. According to the Company, the webcast of the presentations will be
available on the Events & Presentation section of the Company website. The
Full Research Report on Infinity Pharmaceuticals Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/3862_INFI

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Contact: Joe Thomas, +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.